Neuroendocrine Carcinoma | P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Neuroendocrine Carcinoma research study

What is the primary objective of this study?

The primary purpose of the study is to investigate the effects of high-dose octreotide on flushing, diarrhea, and quality of life in patients whose disease-related symptoms are inadequately controlled by the maximum approved dose of octreotide LAR.

Who is eligible to participate?

Inclusion Criteria: - Metastatic neuroendocrine tumors that are considered well or moderately differentiated (or low to intermediate grade). Patients with poorly differentiated neuroendocrine carcinomas or small cell carcinomas are excluded from the study. - Elevated urine 5-hydroxyindoleacetic acid (5-HIAA) - More than 2 bowel-movements per day OR more than 4 flushing episodes per week on average - Patient currently on octreotide LAR 30mg every 3 or 4 weeks (for at least 3 cycles prior to screening) - Age ≥ 18 years - Minimum of four weeks since any major surgery, liver-directed therapy (embolization, etc.) or systemic cancer treatment other than octreotide LAR - Eastern Cooperative Oncology Group (ECOG) performance status ≤2 - Life expectancy > 12 weeks - Reliable contraception should be maintained throughout the study and for 3 months after study drug discontinuation. - Signed informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks by the investigator (or his/her designee) with the aid of written information. Exclusion Criteria: - Known hypersensitivity to somatostatin analogues - Patients with poorly differentiated neuroendocrine cancers - Patients with liver cirrhosis - Patients receiving hemodialysis or peritoneal dialysis - Patients with cachexia who, in the opinion of the investigator, may have difficulty tolerating intramuscular injection - Patients with symptomatic cholelithiasis or biliary events within past five years (who have not undergone cholecystectomy) - Patients with recent history (within 5 years) of pancreatitis - Patients with uncontrolled diabetes (HgA1c >8.0 despite adequate therapy) - Women of child-bearing potential, UNLESS they are using two birth control methods - Women who are pregnant or lactating - HIV positive patients - History of sustained ventricular tachycardia, ventricular fibrillation, advanced heart block, idiopathic syncope thought to be related to ventricular arrhythmia, or congenital long QT syndrome - Risk factors for Torsades de Pointes such as cardiac failure, clinically significant/symptomatic bradycardia - Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study - History of noncompliance to medical regimens or unwillingness to comply with the protocol - Patients who were unable to tolerate or did not benefit from above-label dose octreotide (>30mg) in the past - Concomitant use of other cancer treatments or carcinoid syndrome treatments (whether standard or experimental). Patients should discontinue any concomitant cancer medications more than two weeks prior to screening.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Neuroendocrine Carcinoma

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Octreotide LAROctreotide LAR as outlined in Treatment Arm.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Octreotide Long-acting Release (LAR)Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.

Study Status


Start Date: December 2013

Completed Date: October 2014

Phase: Phase 2

Type: Interventional


Primary Outcome: Number of Participants With Improved Frequency of Diarrhea

Secondary Outcome: Rate of Progression Free Survival (PFS) at 6 Months

Study sponsors, principal investigator, and references

Principal Investigator: Jonathan Strosberg, M.D.

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Collaborator: Novartis

More information:

Discuss Flushing